A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

the latest shift for a tarantella company that has repeatedly switched direction and leadership since first emerging as one of the first CRISPR biotechs a decade ago. Editas will now focus ...

CRISPR Therapeutics recently proved it was capable of getting a drug approved. Next, its oncology and cardiovascular disease programs will need to show value. It may soon face some financial ...

In a potential advance for melanoma patients, researchers at ChristianaCare's Gene Editing Institute have used CRISPR gene editing tools to disable a gene mutation often seen in aggressive forms ...

Short interest in CRISPR Therapeutics AG (NASDAQ:CRSP) increased during the last reporting period, rising from 17.56M to 17.59M. This put 23.42% of the company's publicly available shares short.

CRISPR Technology Market CRISPR Technology Market Dublin, Oct. 31, 2024 (GLOBE NEWSWIRE) -- The "CRISPR Technology Market" report has been added to ResearchAndMarkets.com's offering.The CRISPR ...

HG202 is the first CRISPR/Cas13Y RNA-targeting therapy to enter clinical development and the only clinical-stage CRISPR RNA-editing therapy for age-related macular degeneration Preclinical studies ...